Loading...
  • diabetes
  • In recent years, several attempts to generate small molecules or antibodies that impair glucagon action have been pursued as potential therapeutics for type 2 diabetes. (diabetesjournals.org)
  • Our results demonstrate a new strategy for targeting the GPCRs and further support the concept of antagonizing the glucagon signaling pathway as a potential therapeutic approach for type 2 diabetes. (aspetjournals.org)
  • Antagonizing the glucagon signaling pathway represents an attractive therapeutic approach for the treatment of type 2 diabetes. (aspetjournals.org)
  • The present invention is directed to biphenyl derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity. (patentsencyclopedia.com)
  • en] INTRODUCTION: Despite type 2 diabetes (T2D) being recognized as a bihormonal pancreatic disease, current therapies are mainly focusing on insulin, while targeting glucagon has been long dismissed. (uliege.be)
  • modulate
  • The increased calcium response mediated by secretin in the absence of GLP-1R was paralleled by an increased glucose-dependent insulin response, indicating that the heterodimeric receptor complexes modulate secretin responses. (nih.gov)
  • functional
  • It was further shown that glucagon-producing α-cells are topographically arranged for functional reasons with 91% of α-cells in the islets of Langerhans juxtaposed to β-cells. (diabetesjournals.org)
  • Discovery
  • In addition to the discovery of insulin, the crew of Banting, Best, and Collip observed glucagon action, as they had noticed in their preclinical studies in canines that some of their crude insulin preparations would raise glucose levels in the dog briefly before glucose was lowered ( 2 , 3 ). (diabetesjournals.org)